Tuesday, January 21, 2014

The Motley Fool: Johnson & Johnson Still Driven By Drugs

As another solid quarter goes into the books, Johnson & Johnson (NYSE: JNJ  ) continues to be a med-tech story driven largely by the success of its drug platform. Given the growth potential of the company's platform in immunology, oncology, virology, and metabolic disease, that's not likely to change anytime soon.

Competition may not be the biggest issue for Johnson & Johnson today. While companies like Stryker (NYSE: SYK  ) and Covidien (NYSE: COV  ) are formidable in their own right, and drug companies like AstraZeneca won't just cede markets to the company, the bigger challenge for JNJ may be living up to Wall Street's enthusiasm for the company and meeting some pretty ambitious margin and free cash flow growth targets.

Please read the full article here:
Johnson & Johnson Still Driven By Drugs

No comments: